Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors – overview and clinical implications
Open accessThe DOI matches its Crossref record.
Abstract
Summary: During the past two decades, enormous changes occurred in the management of gastric acid‐related diseases. First, the histamine 2‐receptor antagonists were introduced, offering patients the first single‐agent therapy that effectively reduced gastric acid secretion. Proton pump inhibitors became widely available in the early 1990s, and they generally appeared to be superior to the histamine 2‐receptor antagonists in acid‐suppressing activity, symptom control and healing. Most physicians now use proton pump inhibitors as first‐line treatment for many patients with acid‐peptic disorders, including erosive gastro‐oesophageal reflux disease (GERD), nonerosive reflux disease (NERD) and duodenal and gastric ulcers. Although proton pump inhibitors are often thought to be interchangeable, some differences have emerged in their pharmacological properties, which may be reflected in some aspects of clinical efficacy. Such differences include potency, speed of onset and duration of pH ‘holding times’. Helicobacter pylori has now been recognized as an important factor in the pathogenesis of acid‐peptic disorders. It is clear that H. pylori eradication can dramatically reduce the chronicity of gastric and duodenal ulcers, and accepted therapeutic regimens for H. pylori eradication now include proton pump inhibitors and two or more antibiotics. Although all accepted proton pump inhibitor‐based ‘triple therapies’ are roughly equivalent in efficacy, there is now a shortened regimen available that will potentially enhance compliance and decrease cost. This review examines the relative advantages of proton pump inhibitors vs. histamine 2‐receptor antagonists in the context of acid suppression and in various gastric acid‐related diseases. A brief overview presents the pharmacodynamics and pharmacokinetics of the proton pump inhibitors with particular attention paid to rabeprazole, one of the newer drugs in its class.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
De Palma, G., Lynch, M. D. J., Lu, J., Dang, V. T., Deng, Y., Jury, J., Umeh, G., Miranda, P. M., Pigrau Pastor, M., Sidani, S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6397 · Cited by 505
Systematic review: proton‐pump inhibitor failure in gastro‐oesophageal reflux disease – where next?
FASS, R., SHAPIRO, M., DEKEL, R., & SEWELL, J. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02531.x · Cited by 394
Proton pump inhibitors for functional dyspepsia
Pinto-Sanchez, M. I., Yuan, Y., Hassan, A., Bercik, P., & Moayyedi, P. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011194.pub3 · Cited by 195
Gut Microbiota Composition Before and After Use of Proton Pump Inhibitors
Hojo, M., Asahara, T., Nagahara, A., Takeda, T., Matsumoto, K., Ueyama, H., Matsumoto, K., Asaoka, D., Takahashi, T., Nomoto, K., et al. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5122-4 · Cited by 114
Metadata
- Authors
- Robinson, M.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2004-10-19
- Volume
- 20
- Issue
- s6
- Pages
- 1-10
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W1973130369
- Cited by
- 82
- References
- 0
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors – overview and clinical implications. https://app.cochat.ai/papers/10.1111/j.1365-2036.2004.02160.x
- The paper
- Robinson, M. (2004). Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors – overview and clinical implications. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2004.02160.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.